-
1.发明申请METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY 审中-公开降低因子VIII治疗个体因子VIII的免疫原性的方法公开(公告)号：US20140370035A1
公开(公告)日：2014-12-18
申请号：US14371931
申请日：2013-01-12
CPC分类号： C12Q1/6883 , A61K38/21 , A61K38/37 , A61K39/0008 , A61K47/6811 , A61K47/6815 , A61K2039/6031 , A61K2039/6056 , C07K14/755 , C07K2319/30 , C12Q2600/156 , A61K2300/00
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
摘要翻译： 本公开提供了将具有FVIII和Fc的嵌合和杂合因子VIII（FVIII）多肽施用于具有发展抑制性FVIII免疫应答风险的受试者的方法，所述风险包括抗FVIII抗体和/或细胞介导的免疫。 该施用足以促进凝血并诱导对FVIII的免疫耐受。 嵌合多肽可以包含全长FVIII或含有缺失的FVIII多肽，例如B结构域的完整或部分缺失。
-
2.发明申请公开(公告)号：US20190241960A1
公开(公告)日：2019-08-08
申请号：US16246225
申请日：2019-01-11
IPC分类号： C12Q1/6883 , C07K14/755 , A61K47/68 , A61K39/00 , A61K38/21 , A61K38/37
CPC分类号： C12Q1/6883 , A61K38/21 , A61K38/37 , A61K39/0008 , A61K47/6811 , A61K47/6815 , A61K2039/6031 , A61K2039/6056 , C07K14/755 , C07K2319/30 , C12Q2600/156 , A61K2300/00
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
3.发明授权公开(公告)号：US11286528B2
公开(公告)日：2022-03-29
申请号：US16246225
申请日：2019-01-11
IPC分类号： C07K14/755 , C12Q1/6883 , A61K38/21 , A61K39/00 , A61K38/37 , A61K47/68
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
4.发明授权公开(公告)号：US10221455B2
公开(公告)日：2019-03-05
申请号：US14371931
申请日：2013-01-12
IPC分类号： C07K14/755 , C12Q1/6883 , A61K38/37 , A61K38/21 , A61K39/00 , A61K47/68
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
-
-
搜索结果
4 条记录 (耗时 0.024 秒)
